
[0006] The deleterious effects of IV administration on biologics can be mitigated, in part, through the use of surfactants in formulation development. Non-ionic surfactants, such as polysorbate-20 (PS20) or polysorbate-80 (PS80) are commonly used in protein formulations to protect and stabilize the molecule against air-water interfacial stress (Kerwin, BA. *J. Pharm. Sci.* 97 (2008) 2924-2935). Surfactants can protect the drug product (DP) against surface-induced damage by competing with the protein at both air-water and solid-water interfaces (Kerwin, BA. *J. Pharm. Sci.* 97 (2008) 2924-2935). In addition, surfactants also reduce the surface tension of the system (Cleland, JL., *et al. Critical reviews in therapeutic drug carrier systems* 10 (1993) 307-377). However, a critical drawback in using a non-ionic surfactant at a concentration suitable for IV bag delivery is that prolonged exposure of a biologic to the surfactant can lead to oxidation of specific amino acid residues, thereby reducing therapeutic potency. Lam X, *et al.*, *Pharm Res*. (2011) 28:2543-2555.

[0007] Importantly, prior to IV administration, biologics must also possess a long, stable shelf-life under storage conditions without comprising the structure and activity of the therapeutic protein. Liquid formulations of antibody-drug conjugates (ADCs) employing a linker, for example, may be susceptible to acid-catalyzed hydrolysis of the linker during storage. Such instability can cause premature release of the drug compound upon IV administration to a patient, negatively affecting the pharmacokinetics and safety of the biologic.

[0008] Thus, there is a need for the development of a stable pharmaceutical composition that is both stable for IV administration and possesses a long shelf life under storage conditions. The present disclosure fulfills this need and offers other related advantages.

BRIEF SUMMARY

[0009] In one example, the disclosure provides a pharmaceutical composition including an anti-CD79b immunoconjugate and a surfactant, wherein the surfactant is at a concentration of at least 0.06% w/v (*i.e.*, 0.6 mg/ml) and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID

NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and p is a value from about 1 to about 8 (e.g., between about 2 and about 5, such as about 3.5).

[0010] In some examples, the anti-CD79b immunoconjugate is at a concentration of about 5 mg/ml to about 60 mg/ml, about 10 mg/ml to about 50 mg/ml, about 10 mg/ml to about 40 mg/ml, about 10 mg/ml to about 30 mg/ml, or about 10 mg/ml to about 20 mg/ml.

[0011] In some examples, the anti-CD79b immunoconjugate is at a concentration of about 10 mg/ml to about 20 mg/ml. In one example, the anti-CD79b immunoconjugate is at a concentration of about 10 mg/ml. In another example, the anti-CD79b immunoconjugate is at a concentration of about 20 mg/ml.

[0012] In some examples, the anti-CD79b immunoconjugate is at a concentration of 5 mg/ml to 60 mg/ml, 10 mg/ml to 50 mg/ml, 10 mg/ml to 40 mg/ml, 10 mg/ml to 30 mg/ml, or 10 mg/ml to 20 mg/ml.

[0013] In some examples, the anti-CD79b immunoconjugate is at a concentration of 10 mg/ml to 20 mg/ml. In one example, the anti-CD79b immunoconjugate is at a concentration of 10 mg/ml. In another example, the anti-CD79b immunoconjugate is at a concentration of 20 mg/ml.

[0014] In some examples, the surfactant is at a concentration of between about 0.06% w/v (i.e., 0.6 mg/ml) and about 0.12% w/v (i.e., 1.2 mg/ml). In some examples, the surfactant is at a concentration of at least about 0.06% w/v (*i.e.*, 0.6 mg/ml). In another example, the surfactant is at a concentration of at least about 0.12% w/v (*i.e.*, 1.2 mg/ml). In some examples, the surfactant is at a concentration of at least 0.06% w/v. In another example, the surfactant is at a concentration of at least 0.12% w/v. In some examples, the surfactant is at a concentration of 0.06% w/v. In another example, the surfactant is at a concentration of 0.12% w/v.

[0015] In some examples, the anti-CD79b immunoconjugate is at a concentration of about 10 mg/ml and the surfactant is at a concentration of about 0.06% w/v (*i.e.*, 0.6 mg/ml). In some examples, the anti-CD79b immunoconjugate is at a concentration of about 20 mg/ml and the surfactant is at a concentration of at least about 0.12% w/v. In some examples, the anti-CD79b immunoconjugate is at a concentration of about 20 mg/ml and the surfactant is at a concentration of about 0.12% w/v (i.e., 1.2 mg/ml).

[0016] In some examples, the anti-CD79b immunoconjugate is at a concentration of 10 mg/ml and the surfactant is at a concentration of 0.06% w/v (*i.e.*, 0.6 mg/ml). In some examples, the anti-CD79b immunoconjugate is at a concentration of 20 mg/ml and the surfactant is at a

concentration of at least 0.12% w/v. In some examples, the anti-CD79b immunoconjugate is at a concentration of 20 mg/ml and the surfactant is at a concentration of 0.12% w/v.

[0017] In some examples according to (or as applied to) any of the examples above, the pharmaceutical composition is a liquid pharmaceutical composition. In some examples, the liquid pharmaceutical composition is stable for at least about any one of 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at 30°C, or for at least about any one of 24, 48, or 72 hours upon storage at 2°C-8°C.

[0018] In certain examples of the present disclosure, the surfactant herein is non-ionic. In an exemplary example, the surfactant is chosen from the group consisting of polysorbate 20 (PS20), polysorbate 80 (PS80), poloxamer 188 (P188), N-octyl-β-D glucopyranoside (OG), and a combination thereof. In a specific example, the surfactant is PS20. In still another specific example, the surfactant is PS80.

[0019] In some examples of the present disclosure, the composition further includes a buffering agent. In certain examples, buffering agent is a histidine buffer. In some examples, the buffering agent is a succinate buffer. In a specific example, the succinate buffer is a sodium succinate buffer. In some examples, the sodium succinate buffer is at a concentration of about 10 mM to about 200 mM. In some examples, the sodium succinate buffer is at a concentration of 10 mM to 200 mM. In one example, the sodium succinate buffer is at a concentration of about 10 mM. In another example, the sodium succinate buffer is at a concentration of 10 mM.

[0020] In some examples, the composition of the present disclosure has a pH from about 5.0 to about 6.0. In specific examples, the buffer has a pH of about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, or about 6.0. In one example, the composition of the present disclosure has a pH of about 5.3. In some examples, the composition of the present disclosure has a pH from 5.0 to 6.0. In specific examples, the buffer has a pH of 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0. In one example, the composition of the present disclosure has a pH of 5.3.


[0021] In certain examples of the present disclosure, the composition further includes a sugar. In some examples, the sugar is at a concentration of about 100 mM to about 260 mM. In some examples, the sugar is at a concentration of 100 mM to 260 mM. In some examples, the sugar is selected from the group consisting of: sucrose, mannitol, sorbitol, glycerol, dextran 40, and trehalose.

[0022] In a specific example, the sugar is sucrose. In one example of the present disclosure, sucrose is at a concentration of about 120 mM. In another example, sucrose is at a concentration of 120 mM.

[0023] In some examples, the composition of the present disclosure is lyophilized (such as a lyophilized cake). In some examples, the lyophilized composition is contained in a vial, e.g., a 20-ml glass vial.

[0023a] In one aspect, the present disclosure refers to a liquid composition comprising an anti-CD79b immunoconjugate, a buffering agent, a sugar, and a surfactant, wherein:

the anti-CD79b immunoconjugate is at a concentration between 5 mg/ml and 60 mg/ml;
the buffering agent is at a concentration between 10 mM and 200 mM;
the sugar is at a concentration between 100 mM and 260 mM;
the surfactant is polysorbate 20 at a concentration between 1.0 mg/ml and 1.4 mg/ml,
wherein the pH of the liquid composition is between 5.0 and 6.0, and
wherein the anti-CD79b immunoconjugate comprises the formula:




wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and

p is a value from 1 to 8.

[0023b] In one aspect, the present disclosure refers to a lyophilized composition comprising 140-150 mg or 30 mg of an anti-CD79b immunoconjugate, 8.4-9.0 mg or 1.8 mg polysorbate 20, 8.27-8.88 mg or 1.77 mg succinic acid, 3.80-4.08 mg or 0.816 mg sodium hydroxide, and 288-309 mg or 61.8 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:


Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and

p is a value from 1 to 8.

[0023c] In one aspect, the present disclosure refers to a liquid composition produced by reconstituting the lyophilized composition as described above.

[0023d] In one aspect, the present disclosure refers to a glass vial containing the liquid composition as described above or the lyophilized composition as described above.


[0024] In one example, the present disclosure provides a pharmaceutical composition produced by lyophilization of a liquid formulation including 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid formulation has a pH of 5.3, and wherein the anti-CD79b immunoconjugate has the formula:



wherein:
Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and p is a value from about 1 to about 8 (e.g., between about 2 and about 5, such as about 3.5).

[0025] In some examples of the present disclosure, the anti-CD79b antibody comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some examples, the heavy chain comprises the amino acid sequence of SEQ ID NO: 9 and the light chain comprises the amino acid sequence of SEQ ID NO: 10.

[0026] Also provided is a pharmaceutical composition produced by lyophilization of a liquid formulation comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid formulation has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 9, the light chain comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5 (such as about 3.5). In some examples, the pharmaceutical composition is a lyophilized cake.


[0027] In certain examples, the pharmaceutical composition of the present disclosure has a stability of about 60 months at 5°C ± 3°C when protected from light. In certain example, the pharmaceutical composition of the present disclosure has a stability of about 48 months at 5°C ± 3°C when protected from light.

[0028] In some examples, the stability of the pharmaceutical composition of the present disclosure is measured by size-exclusion chromatography high performance (SE-HPLC). In one example, the composition has a main peak (area %) of at least 95.0 as measured by SE-HPLC.

[0029] In some examples, the stability of the pharmaceutical composition of the present disclosure is measured by imaged capillary isoelectric focusing (icIEF). In one example, the composition has a main peak (area %) of at least 58.0, an acid region (area %) of at most 32.0, and a basic region (area %) of at most 12.0 as measured by icIEF.


[0030] In certain examples, the pharmaceutical composition of the present disclosure is reconstituted with sterile water for injection (SWFI). In some examples, the pharmaceutical composition is reconstituted in about 7.2 ml SWFI. In some examples, the reconstituted composition is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30°C. In some examples, the reconstituted composition is stable for at least 24, 48, or 72 hours upon storage at about 2°C to about 8°C. In some examples, the reconstituted composition is further diluted into an isotonic buffer in an intravenous (IV) bag. In some examples, the final volume of the diluted composition in the IV bag is between about 50 ml and about 100 ml. In some examples, the concentration of the immunoconjugate in the IV bag is between about 0.72 mg and about 2.7 mg.

[0031] Also provided herein is a pharmaceutical composition produced by lyophilization of a liquid formulation comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid formulation has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 9, the light chain comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5 (such as about 3.5).

[0031a] In one aspect, the present disclosure refers to a liquid composition for intravenous administration comprising a) between 0.72 and 2.7 mg/ml of an anti-CD79b immunoconjugate; b) between 0.36 and 1.35 mM sodium succinate; c) between 0.51 and 16.24 mM sucrose; d) between 0.0432 and 0.162 mg/ml polysorbate 20, wherein the pH of the liquid composition is between 5 and 5.7, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and


p is a value from 1 to 8.

[0031b] In one aspect, the present disclosure refers to a liquid composition for intravenous administration obtained by diluting the liquid composition as described above in an isotonic buffer.

[0031c] In one aspect, the present disclosure refers to an intravenous (IV) bag containing the liquid composition as described above.

[0032] Provided is a liquid composition (such as for intravenous administration) comprising a) bewtween about 0.72 and about 2.7 mg/ml polatuzumab vedotin; b) between about 0.36 and about 1.35 mM sodium succinate; c) between about 0.51 and about 16.24 mM sucrose; d) between about 0.0432 and about 0.162 mg/ml polysorbate 20, wherein the pH of the liquid composition is between about 5 and about 5.7. Also provided is a liquid composition (such as for intravenous administration) comprising a) about 0.72 mg/ml polatuzumab vedotin; b) about 0.36 mM sodium succinate; c) about 0.51 mM sucrose; d) about 0.0432 mg/ml polysorbate 20, wherein the pH of the liquid composition is between 5.1 and about 5.4. Also provided is a liquid composition (such as for intravenous administration)comprising a) about 2.7 mg/ml polatuzumab vedotin; b) about 1.35 mM sodium succinate; c) about 16.24 mM sucrose; d) about 0.162 mg/ml polysorbate 20, wherein the pH of the liquid composition is between about 5.1 and about 5.4. In some example, the volume of the liquid composition is between about 50 ml and about 100 ml. In some examples, the volume of the liquid composition is 50 ml. In some examples, the volume of the liquid composition is 100 ml. In some examples, the liquid composition is contained in an intravenous (IV) bag. In some examples, the surfaces of the IV bag that contact the liquid composition are composed of polyvinylchloride (PVC), polyolefin (PO), polyethylene (PE), or polypropylene (PE).

[0033] In one example, the present disclosure provides a pharmaceutical composition comprising an anti-CD79b immunoconjugate, a surfactant, a succinate buffer, and a sugar, wherein the pharmaceutical composition, when reconstituted in water, forms a liquid formulation comprising the anti-CD79b immunoconjugate at a concentration of about 10 mg/ml to about 20 mg/ml, the surfactant at a concentration of at least 0.06% w/v (*i.e.*, 0.6 mg/ml), the succinate buffer at a concentration of about 10 mM to about 200 mM, and the sugar at a concentration of about 100 mM to about 260 mM, wherein the liquid formulation has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and p is a value from about 1 to about 8 (e.g., between about 2 and about 5, such as about 3.5). In some examples, the anti-CD79b antibody comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some examples, the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10.


[0034] In some examples, the pharmaceutical composition is reconstituted in SWFI and subsequently diluted into a buffer in an IV bag. In certain examples, the pharmaceutical composition is reconstituted in SWFI and subsequently diluted into an isotonic buffer in an IV bag. In one example, the surfactant concentration upon dilution in the IV bag is at least 0.003% w/v. In one example, the surfactant concentration upon dilution in the IV bag is at least 0.004% w/v. In some examples, the surfactant is polysorbate 20. In some examples, the sugar is sucrose. In a specific example, the sucrose is at a concentration of 120 mM. In some examples, the succinate buffer is a sodium succinate buffer. In a specific example, the sodium succinate buffer is at a concentration of 10 mM. In some examples, pharmaceutical composition, following reconstitution, is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30°C. In some examples, the pharmaceutical composition, following reconstitution, is stable for at least 24, 48, or 72 hours upon storage at about 2°C to about 8°C.

[0035] In some examples, the pharmaceutical composition, when reconstituted in water, has a stability of up to about 1 day, up to about 2 days, or up to about 3 days at 30°C. In some examples, the pharmaceutical composition, when reconstituted in water, has a stability of up to about 1 day, up to about 2 days, up to about 3 days, up to about 4 days, up to about 5 days, up to 6 days, or up to about 7 days at 5°C ± 3°C. In certain examples, the stability of the composition is measured by size-exclusion high performance liquid chromatography (SE-HPLC). In a specific example, the composition has a main peak (area %) of at least 95.0 as measured by SE-HPLC.

[0036] In certain examples, the stability of the composition is measured by imaged capillary isoelectric focusing (icIEF). In a specific example, the composition has a main peak (area %) of at least 58.0, an acid region (area %) of at most 32.0, and a basic region (area %) of at most 12.0 as measured by icIEF.


[0037] In some examples, a pharmaceutical composition disclosed herein is contained in a glass vial (e.g., a 20 ml glass vial). In some examples, the pharmaceutical composition is a lyophilized pharmaceutical composition. In some examples, the pharmaceutical composition is a liquid pharmaceutical composition.

[0038] In one example, the present disclosure provides a pharmaceutical composition produced by a process comprising the steps of: (a) lyophilization of a liquid composition comprising 20 mg/ml of an anti-CD79b immunoconjugate in 10 mM sodium succinate buffer, 0.12% w/v of polysorbate 20, and 120 mM sucrose, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein: Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 9, the light chain comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5, to produce a lyophilized composition; (b) reconstituting the lyophilized composition with about 7.2 ml sterile water for injection (SWFI) to produce a reconstituted composition; and (c) diluting the reconstituted composition into an isotonic buffer in an intravenous (IV) bag to produce the pharmaceutical composition, wherein the final volume of the pharmaceutical composition in the IV bag is about 100 ml, and wherein the final concentration of the immunoconjugate in the pharmaceutical composition is about 0.72 mg/ml or about 2.7 mg/ml.

[0039] In one example, the present disclosure provides a liquid composition comprising an anti-CD79b immunoconjugate, a surfactant, a succinate buffer, and a sugar, wherein the anti-CD79b immunoconjugate is at a concentration of about 10 mg/ml to about 20 mg/ml, the surfactant is at a concentration of at least 0.06% w/v (*i.e.*, 0.6 mg/ml), the succinate buffer is at a concentration of about 10 mM to about 200 mM, and the sugar is at a concentration of about 100 mM to about 260 mM, wherein the liquid composition has a pH of 5.3, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and p is a value from about 1 to about 8 (e.g., between about 2 and about 5, such as about 3.5). In some examples, the anti-CD79b antibody comprises a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some examples, the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10.

[0040] In some examples, the surfactant is polysorbate 20. In some examples, the sugar is sucrose. In a specific example, the sucrose is at a concentration of 120 mm. In some examples, the succinate buffer is a sodium succinate buffer. In a specific example, the sodium succinate buffer is at a concentration of 10 mM.

[0041] In some examples, the liquid composition of the present disclosure is diluted into in an isotonic buffer. In an exemplary example, the liquid composition of the present disclosure dissolved in an isotonic buffer is in an IV bag. In some examples, the isotonic buffer into which the liquid composition is diluted is an 0.9% sodium chloride solution, an 0.45% sodium chloride solution, or a 5% dextrose solution.


[0042] In some examples, a liquid composition provided herein that has been diluted in 0.9% sodium chloride solution is stable (according to any one or more criteria described elsewhere herein) following dilution for up to at least about 24 hours at 2°C-8°C. In some examples, a liquid composition provided herein that has been diluted in 0.9% sodium chloride solution is stable (according to any one or more criteria described elsewhere herein) following dilution for up to about 4 hours at 9°C to 25°C. In some examples, a liquid composition provided herein that has been diluted in 0.45% sodium chloride solution is stable (according to any one or more criteria described elsewhere herein) following dilution for up to at least about 24 hours at 2°C-8°C. In some examples, a liquid composition provided herein that has been diluted in 0.45% sodium chloride

solution is stable (according to any one or more criteria described elsewhere herein) following dilution for up to about 4 hours at 9°C to 25°C. In some examples, a liquid composition provided herein that has been diluted in 5% dextrose solution is stable (according to any one or more criteria described elsewhere herein) following dilution for up to at least about 48 hours at 2°C-8°C. In some examples, a liquid composition provided herein that has been diluted in5% dextrose solution is stable (according to any one or more criteria described elsewhere herein) following dilution for up to about 8 hours at 9°C to 25°C.

[0043] In some examples, the liquid composition that is diluted in an isotonic buffer is in an IV bag. In some examples, the surfaces of the IV bag that contact the composition that is diluted in an isotonic buffer are composed of polyvinylchloride (PVC), polyolefin (PO), polyethylene (PE), or polypropylene (PE).

[0044] In some examples, the liquid composition of the present disclosure diluted in an isotonic buffer in an IV bag has a stability of up to about 6 to about 8 hours at 30°C. In some examples, the liquid composition of the present disclosure dissolved in an isotonic buffer in an IV bag has a stability of up to about 24 hours at 25°C. In some examples, the liquid composition of the present disclosure dissolved in an isotonic buffer in an IV bag has a stability of up to about 72 hours at 5°C ± 3°C. In certain examples, the isotonic buffer is normal saline. In some examples, the liquid composition is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30°C. In some examples, the liquid composition is stable for at least 24, 48, or 72 hours upon storage at about 2°C to about 8°C.


[0045] Also provided is lyophilized pharmaceutical composition comprising about 150 mg of an anti-CD79b immunoconjugate, about 9.0 mg polysorbate 20, about 8.88 mg succinic acid, about 4.08 mg sodium hydroxide, and about 309 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:



wherein Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5 (such as about 3.5). In some examples, the lyophilized composition (such as a cake) is contained in a vial, e.g., a 20 ml glass vial.

[0046] Further provided is a lyophilized pharmaceutical composition comprising about 150 mg of polatuzumab vedotin, about 9.0 mg polysorbate 20, about 8.88 mg succinic acid, about 4.08 mg sodium hydroxide, and about 309 mg sucrose. In some examples, the lyophilized composition (such as a cake) is contained in a vial, e.g., a 20 ml glass vial.


[0047] Also provided is a lyophilized pharmaceutical composition comprising about 140 mg of an anti-CD79b immunoconjugate, about 8.4 mg polysorbate 20, about 8.27 mg succinic acid, about 3.80 mg sodium hydroxide, and about 288 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:



wherein b is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5 (such as about 3.5). In some examples, the lyophilized composition (such as a cake) is contained in a vial, e.g., a 20 ml glass vial.

[0048] Further provide is a lyophilized pharmaceutical composition comprising about 140 mg of polatuzumab vedotin, about 8.4 mg polysorbate 20, about 8.27 mg succinic acid, about 3.80 mg sodium hydroxide, and about 288 mg sucrose. In some examples, the lyophilized composition (such as a cake) is contained in a vial, e.g., a 20 ml glass vial.

[0049] Also provided is a lyophilized pharmaceutical composition comprising about 30 mg of an anti-CD79b immunoconjugate, about 1.8 mg polysorbate 20, about 1.77 mg succinic acid, about 0.816 mg sodium hydroxide, and about 61.8 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:



wherein Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the heavy chain of the anti-CD79b comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid

sequence of SEQ ID NO: 10; Val is valine; Cit is citrulline; and p is a value from about 2 to about 5 (such as about 3.5). In some examples, the lyophilized composition is a lyophilized cake. In some examples, the lyophilized composition (such as a cake) is contained in a vial, e.g., a 20 ml glass vial.

[0050] Further provided is a lyophilized pharmaceutical composition comprising about 30 mg of polatuzumab vedotin, about 1.8 mg polysorbate 20, about 1.77 mg succinic acid, about 0.816 mg sodium hydroxide, and about 61.8 mg sucrose. In some examples, the lyophilized composition (such as a cake) is contained in a vial, e.g., a 20 ml glass vial.

[0051] In some examples, a lyophilized pharmaceutical composition provided herein is a lyophilized cake. In some examples, a lyophilized pharmaceutical composition according to any of the examples herein is stable for at least 6, 12, 18, 24, 30, 36, 42, 48, 54, or 60 months upon storage at about 2°C to about 8°C.

[0052] Provided is a liquid pharmaceutical composition comprising a) between about 5-60 mg/ml polatuzumab vedotin; b) between about10-200 mM sodium succinate; c) between about 100-260 mM sucrose; and d) between about 0.06-0.12% w/v polysorbate 20, wherein the pH of the liquid compositions is between 5 and 6. In some examples, the liquid pharmaceutical composition comprises a) bewtween about 10-55 mg/ml polatuzumab vedotin; b) between about 10-100 mM sodium succinate; c) between about 150-260 mM sucrose; and d) between about 0.08-0.12% w/v polysorbate 20, wherein the pH of the liquid compositions is between 5.1 and 5.6. In some examples, the liquid pharmaceutical composition comprises a) between about 15-40 mg/ml polatuzumab vedotin; b) between about 10-50 mM sodium succinate; c) between about 200-260 mM sucrose; and d) between about 0.1-0.12% w/v polysorbate 20, wherein the pH of the liquid compositions is between 5.2 and 5.4. In some examples, the liquid composition is obtained by reconstituting a lyophilized composition (such as a cake). In some examples, the liquid composition is contained in a vial, e.g., a 20 ml glass vial.

[0053] Also provided is a liquid pharmaceutical composition comprising a) 20 mg/ml polatuzumab vedotin; b) 10 mM sodium succinate; c) 120 mM sucrose; and d) 0.12% w/v polysorbate 20, wherein the pH of the liquid compositions is about 5.3. In some examples, the liquid composition is obtained by reconstituting a lyophilized composition (such as a cake). In some examples, the liquid composition is contained in a vial, e.g., a 20 ml glass vial.

[0054] In some examples, a liquid composition according to any of the examples herein is stable for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours upon storage at about 30°C. In some examples, a liquid composition according to any of the examples herein is stable for at least

24, 48, or 72 hours upon storage at about 2°C to about 8°C. In some examples, the liquid composition is obtained by reconstituting a lyophilized composition (such as a cake). In some examples, the liquid composition is contained in a vial, e.g., a 20 ml glass vial.

[0055] In some examples, a reconstituted pharmaceutical composition provided herein is stable after 72 hours of storage at 2°C–8°C. In some examples, a reconstituted pharmaceutical composition provided herein is stable after 24 hours of storage at 30°C with exposure to ambient light. In some examples, the reconstituted pharmaceutical composition compriuses a20 mg/mL polatuzumab vedotin in 10 mM succinate, 120 mM sucrose, and1.2 mg/mL polysorbate 20, wherein the pH is 5.3. In some examplethe affinity of polatuzumab vedotin for its target (i.e., CD79b) or in the biological activity of polatuzumab vedotin

[0056] In one example, the present disclosure provides a method of treating a proliferative disorder in a patient in need thereof including administering to a patient the pharmaceutical composition or a liquid composition described herein. Also provided is the use of a pharmaceutical composition or liquid composition described herein for the manufacture of a medicament for treating a proliferative disorder in a patient in need thereof. In some examples, provided is a pharmaceutical composition or liquid composition described herein for use in the treatment of a proliferative disorder in a patient in need thereof. Also provided is a pharmaceutical composition or a liquid composition described herein for use in a method of treating a proliferative disorder in a patient in need thereof.

[0057] In some examples, the proliferative disorder is cancer. In an exemplary example, the cancer is a B cell proliferative disorder. In specific examples, the B cell proliferative disorder is selected from the group consisting of: lymphoma, myeloma, non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), relapsed/refractory DLBCL aggressive NHL, indolent lymphoma, follicular lymphoma (FL), relapsed aggressive NHL, relapsed indolent NHL, relapsed NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma.

[0058] In one example of the present disclosure, the B cell proliferative disorder is non-Hodgkin's lymphoma (NHL). In one example, the B cell proliferative disorder is diffuse large B-cell lymphoma (DLBCL). In one example, the B cell proliferative disorder is relapsed/refractory DLBCL. In some examples, the B cell proliferative disorder is relapsed/refractory DLBCL. In another example, the B cell proliferative disorder is relapsed NHL or refractory NHL. In still another example, the B cell proliferative disorder is follicular lymphoma (FL).

[0058a] In one aspect, the present disclosure refers to use of the liquid composition as described above, the lyophilized composition as described above, or the liquid composition for intravenous administration as described above, in the manufacture of a medicament for treating a B cell proliferative disorder in a patient in need thereof.

CLAIMS

What is claimed is:

1. A liquid composition comprising an anti-CD79b immunoconjugate, a buffering agent, a sugar, and a surfactant, wherein:

the anti-CD79b immunoconjugate is at a concentration between 5 mg/ml and 60 mg/ml;


the buffering agent is at a concentration between 10 mM and 200 mM;

the sugar is at a concentration between 100 mM and 260 mM;

the surfactant is polysorbate 20 at a concentration between 1.0 mg/ml and 1.4 mg/ml,

wherein the pH of the liquid composition is between 5.0 and 6.0, and

wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and

p is a value from 1 to 8.

2. The liquid composition of claim 1, wherein the anti-CD79b immunoconjugate is at a concentration of 10 mg/ml to 20 mg/ml.

3. The liquid composition of claim 1 or claim 2, wherein the anti-CD79b immunoconjugate is at a concentration of 20 mg/ml.

4. The liquid composition of any one of claims 1-3, wherein the buffering agent is a histidine buffer or a succinate buffer.

5. The liquid composition of any one of claims 1-4, wherein the buffering agent is a histidine buffer.

6. The liquid composition of any one of claims 1-4, wherein the buffering agent is a succinate buffer.

7. The liquid composition of claim 6, wherein the succinate buffer is a sodium succinate buffer.

8. The liquid composition of claim 7, wherein the sodium succinate buffer is at a concentration of 10 mM.

9. The liquid composition of any one of claims 1-8, wherein the liquid composition has a pH of 5.3.

10. The liquid composition of any one of claims 1-9, wherein the sugar is selected from the group consisting of: sucrose, mannitol, sorbitol, glycerol, dextran 40, and trehalose.

11. The liquid composition of any one of claims 1-10, wherein the sugar is sucrose.

12. The liquid composition of claim 11, wherein the sucrose is at a concentration of 120 mM.

13. The liquid composition of any one of claims 1-12, wherein the surfactant is polysorbate 20 at a concentration of 0.12% w/v or 1.2 mg/ml.

14. The liquid composition of any one of claims 1-4 and 6-13, wherein the anti-CD79b immunoconjugate is at a concentration of 20 mg/ml, the buffering agent is a sodium succinate buffer at a concentration of 10 mM, the surfactant is polysorbate 20 at a concentration of 0.12% w/v or 1.2 mg/ml, and the sugar is sucrose at a concentration of 120 mM, and wherein the liquid composition has a pH of 5.3.

15. The liquid composition of any one of claims 1-14, wherein the liquid composition has been reconstituted from a lyophilized composition.

16. The liquid composition of claim 15, wherein the lyophilized composition is a lyophilized cake.


17. The liquid composition of claim 15 or claim 16, wherein the liquid composition has been reconstituted with sterile water for injection (SWFI).

18. The liquid composition of any one of claims 15-17, wherein the liquid composition has been reconstituted with 7.2 ml sterile water for injection (SWFI).

19. The liquid composition of any one of claims 1-18, wherein the liquid composition is stable for at least 24 hours upon storage at 30°C.

20. The liquid composition of any one of claims 1-19, wherein the liquid composition is stable for at least 72 hours upon storage at 2°C to 8°C.

21. A lyophilized composition comprising 140-150 mg or 30 mg of an anti-CD79b immunoconjugate, 8.4-9.0 mg or 1.8 mg polysorbate 20, 8.27-8.88 mg or 1.77 mg succinic acid, 3.80-4.08 mg or 0.816 mg sodium hydroxide, and 288-309 mg or 61.8 mg sucrose, wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and

p is a value from 1 to 8.

22. The lyophilized composition of claim 21, wherein the lyophilized composition comprises 150 mg of the anti-CD79b immunoconjugate, 9.0 mg polysorbate 20, 8.88 mg succinic acid, 4.08 mg sodium hydroxide, and 309 mg sucrose.

23. The lyophilized composition of claim 21, wherein the lyophilized composition comprises 140 mg of the anti-CD79b immunoconjugate, 8.4 mg polysorbate 20, 8.27 mg succinic acid, 3.80 mg sodium hydroxide, and 288 mg sucrose.

24. The lyophilized composition of claim 21, wherein the lyophilized composition comprises 30 mg of the anti-CD79b immunoconjugate, 1.8 mg polysorbate 20, 1.77 mg succinic acid, 0.816 mg sodium hydroxide, and 61.8 mg sucrose.

25. The lyophilized composition of any one of claims 21-24, wherein the lyophilized composition is stable for at least 6 months upon storage at 2°C to 8°C.

26. The lyophilized composition of any one of claims 21-25, wherein the lyophilized composition is stable for at least 7 months upon storage at 25°C over a residual moisture content range of 0.3% (w/w) to 3.2% (w/w).

27. The lyophilized composition of any one of claims 21-26, wherein the lyophilized composition is a lyophilized cake.


28. A liquid composition produced by reconstituting the lyophilized composition of any one of claims 21-27.

29. The liquid composition of claim 28, wherein the lyophilized composition is reconstituted with sterile water for injection (SWFI).

30. The liquid composition of claim 28 or claim 29, wherein the lyophilized composition is reconstituted with 7.2 ml sterile water for injection (SWFI).

31. A glass vial containing the liquid composition of any one of claims 1-20 and 28-30, or the lyophilized composition of any one of claims 21-27.

32. A liquid composition for intravenous administration comprising a) between 0.72 and 2.7 mg/ml of an anti-CD79b immunoconjugate; b) between 0.36 and 1.35 mM sodium succinate; c) between 0.51 and 16.24 mM sucrose; d) between 0.0432 and 0.162 mg/ml polysorbate 20, wherein the pH of the liquid composition is between 5 and 5.7, and wherein the anti-CD79b immunoconjugate comprises the formula:



wherein:

Ab is an anti-CD79b antibody, wherein the anti-CD79b antibody comprises a heavy chain and a light chain, wherein the light chain comprises (a) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 1); (b) an HVR-L2 sequence of AASNLES (SEQ ID NO: 2); and (c) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 3); wherein the heavy chain comprises (a) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 4); (b) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 5); and (c) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 6); Val is valine; Cit is citrulline; and

p is a value from 1 to 8.

33. The liquid composition of claim 32, comprising: a) 0.72 mg/ml of the anti-CD79b immunoconjugate; b) 0.36 mM sodium succinate; c) 0.51 mM sucrose; and d) 0.0432 mg/ml polysorbate 20, wherein the pH of the liquid composition is between 5.1 and 5.4.

34. The liquid composition of claim 32, comprising: a) 2.7 mg/ml of the anti-CD79b immunoconjugate; b) 1.35 mM sodium succinate; c) 16.24 mM sucrose; and d) 0.162 mg/ml polysorbate 20, wherein the pH of the liquid composition is between 5.1 and 5.4.

35. The liquid composition of any one of claims 32-34, wherein the pH of the liquid composition is 5.3.

36. The liquid composition of any one of claims 32-35, wherein the ratio of the anti-CD79b immunoconjugate to the polysorbate 20 in the composition is 0.72 mg/ml:0.0432 mg/ml.

37. A liquid composition for intravenous administration obtained by diluting the liquid composition of any one of claims 1-20 and 28-30 in an isotonic buffer.

38. The liquid composition of claim 37, wherein the isotonic buffer is a 0.9% sodium chloride solution, a 0.45% sodium chloride solution, or a 5% dextrose solution.

39. The liquid composition of claim 37 or claim 38, wherein the surfactant concentration following dilution is at least 0.004% w/v.

40. The liquid composition of any one of claims 32-39, wherein the volume of the liquid composition is between 50 ml and 100 ml.

41. The liquid composition of claim 40, wherein the volume of the liquid composition is 50 ml.

42. The liquid composition of claim 40, wherein the volume of the liquid composition is 100 ml.

43. The liquid composition of any one of claims 32-42, wherein the liquid composition is in an intravenous (IV) bag.

44. An intravenous (IV) bag containing the liquid composition of any one of claims 32-42.

45. The liquid composition of any one of claims 1-20 and 28-30, the lyophilized composition of any one of claims 21-27, or the liquid composition for intravenous administration of any one of claims 32-43, wherein the anti-CD79b antibody comprises a heavy chain variable domain (VH) comprising the amino acid sequence

of SEQ ID NO: 7 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 8.

46. The liquid composition of any one of claims 1-20, 28-30, and 45, the lyophilized composition of any one of claims 21-27 and 45, or the liquid composition for intravenous administration of any one of claims 32-43 and 45, wherein the heavy chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 9, and wherein the light chain of the anti-CD79b antibody comprises the amino acid sequence of SEQ ID NO: 10.

47. The liquid composition of any one of claims 1-20, 28-30, and 45-46, the lyophilized composition of any one of claims 21-27 and 45-46, or the liquid composition for intravenous administration of any one of claims 32-43 and 45-46, wherein p is a value from 2 to 5.

48. The liquid composition of any one of claims 1-20, 28-30, and 45-47, the lyophilized composition of any one of claims 21-27 and 45-47, or the liquid composition for intravenous administration of any one of claims 32-43 and 45-47, wherein p is about 3.5.

49. The liquid composition of any one of claims 1-20, 28-30, and 45-48, the lyophilized composition of any one of claims 21-27 and 45-48, or the liquid composition for intravenous administration of any one of claims 32-43 and 45-48, wherein the anti-CD79b immunoconjugate is polatuzumab vedotin.

50. The liquid composition of claim 1, wherein a) the immunoconjugate is polatuzumab vedotin; b) the buffering agent is sodium succinate; and c) the sugar is sucrose, wherein the ratio of said polatuzumab vedotin : sodium succinate : sucrose : polysorbate 20 is 20 mg/ml : 10 mM : 120 mM : 1.2 mg/ml, wherein the pH of the liquid composition is between 5.1 and 5.4.

51. The liquid composition of claim 50, wherein said polatuzumab vedotin is at a concentration between 5 mg/ml and 60 mg/ml.

52. Use of the liquid composition of any one of claims 1-20, 28-30, and 45-51, the lyophilized composition of any one of claims 21-27 and 45-49, or the liquid composition for intravenous administration of any one of claims 32-43 and 45-49 in the manufacture of a medicament for treating a B cell proliferative disorder in a patient in need thereof.

53. The use of claim 52, wherein the B cell proliferative disorder is selected from the group consisting of: lymphoma, myeloma, non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), aggressive NHL, indolent lymphoma, follicular lymphoma (FL), relapsed aggressive NHL, relapsed indolent NHL, relapsed NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma.

54. The use of claim 53, wherein the B cell proliferative disorder is non-Hodgkin's lymphoma (NHL).

55. The use of claim 53, wherein the B cell proliferative disorder is diffuse large B-cell lymphoma (DLBCL).

56. The use of claim 53, wherein the B cell proliferative disorder is relapsed NHL or refractory NHL.

57. The use of claim 53, wherein the B cell proliferative disorder is follicular lymphoma (FL).

58. The use of claim 53, wherein the B cell proliferative disorder is relapsed/refractory diffuse large B-cell lymphoma (DLBCL).